Puma Biotechnology (NASDAQ:PBYI - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.29, Zacks reports. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Puma Biotechnology Stock Performance
Shares of Puma Biotechnology stock traded down $0.23 on Monday, reaching $3.35. The stock had a trading volume of 918,837 shares, compared to its average volume of 574,671. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. The business's 50-day moving average price is $3.02 and its two-hundred day moving average price is $2.86. The stock has a market cap of $164.44 million, a P/E ratio of 6.98 and a beta of 1.09. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $6.05.
Analyst Upgrades and Downgrades
PBYI has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday. StockNews.com upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Friday.
Check Out Our Latest Stock Report on PBYI
Insider Activity at Puma Biotechnology
In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the sale, the insider now directly owns 108,951 shares in the company, valued at approximately $343,195.65. This represents a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by company insiders.
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Read More
Before you consider Puma Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Puma Biotechnology wasn't on the list.
While Puma Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
